Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Peter Michael Huelsmann

Dieter Heindl

Olaf Mundigl

Guy Georges

Erhard Kopetzki

Stefan Dengl

Joerg Moelleken

Guido Hartmann

Christian Gassner

Hubert Kettenberger

Joerg Thomas Regula

Sabine Gruener

Sebastian Breuer

Sabine Imhof-Jung

Michael Molhoj

Ralf Schumacher

Georg Tiefenthaler

Kristian Hobolt Jensen

Hendrik Knoetgen

Roland Beckmann

Joerg Benz

Gerhard Niederfellner

Barbara Weiser

Stefan Lorenz

Marc Bedoucha

Brigitte Kaluza

The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.

Antibody that binds to VEGF and IL-1beta and methods of use

Herein is reported an expression vector comprising &#x2014;an antibody light chain expression cassette, &#x2014;an antibody heavy chain expression cassette, and &#x2014;a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5' to 3&#x2032; sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies.

Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides

Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.

Bispecific antibodies and methods of use in ophthalmology

Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.

Anti-ANG2 antibodies and methods of use

Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.

Anti-IL-1beta antibodies

Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.

Anti-PDGF-B antibodies and methods of use

Herein is reported an expression vector comprising&#x2014;an antibody light chain expression cassette, &#x2014;an antibody heavy chain expression cassette, and&#x2014;a selection marker expression cassette, wherein the expression cassettes are arranged unidirectional, and wherein the expression cassettes are arranged in the 5' to 3&#x2032; sequence of antibody heavy chain expression cassette, antibody light chain expression cassette and selection marker expression cassette. Further are reported herein methods for the generation of antibody producing cells and the use of these cells for the recombinant production of antibodies.

Growing community of inventors

Habach, Germany

Peter Michael Huelsmann